Rubicon Research Q3 FY26 Earnings Call Transcript Released
Rubicon Research reported Q3 FY26 revenue of ₹476 crore (up 52% YoY) and PAT of ₹73 crore (up 91% YoY). EBITDA was ₹112 crore (up 59% YoY). The Pithampur facility is expected to be operational by mid-2026, with commercialization in Q1 CY27. R&D productivity is improving, and the company maintains EBITDA margin guidance of 22-23%. Dr. Pradnya Saravade was appointed as an Independent Director.
The announcement details strong financial performance, strategic capacity expansion plans (Pithampur facility), and positive outlook on R&D productivity and future growth, which are material factors for investors and the market.
The company reported significant year-on-year growth in revenue, EBITDA, and profit after tax. Positive commentary on future growth drivers, R&D productivity, and operational milestones (Pithampur facility) contribute to a positive sentiment.
Rubicon Research Limited (formerly Rubicon Research Private Limited) has released the transcript of its Q3 FY 2025-26 earnings conference call, which was held on February 3, 2026. The transcript is available on the company's website.
During the call, the company reported strong financial performance for the third quarter. Revenue from operations stood at ₹476 crore, a 52% increase year-on-year. EBITDA was ₹112 crore, up 59% year-on-year, and profit after tax was ₹73 crore, an increase of 91% year-on-year. For the first nine months of FY26, revenue was ₹1,240 crore, a 34% increase, with EBITDA at ₹287 crore (up 73% year-on-year).
The company highlighted an increase in inventory to ₹685 crore, viewed as fuel for growth and covering recent and upcoming launches. Return on Capital Employed (ROCE) was reported at 34%. The Pithampur manufacturing facility is on track for operationalization by mid-2026, with commercialization expected in Q1 CY27. The company reiterated its guidance for operating EBITDA margins to remain stable between 22% to 23% and R&D expenses to be around 10% to 11% of revenue for the next several years.
Rubicon Research also announced the appointment of Dr. Pradnya Saravade as an Independent Director. General Atlantic's nominee, Mr. Anand Agarwal, has stepped down from the board. The company emphasized its R&D engine as a key growth driver, with R&D productivity showing an improving trend, moving from 3.3x to 5.7x over different periods. The management expressed confidence in sustained growth driven by a strong pipeline, including specialty products, drug-device combinations, and branded products.
What to do with a filing like this
Rubicon Research Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Rubicon Research Limited. Read the original for the full detail.